Siglec—8, a Novel Selective Target for Eosinophilic Gastrointestinal Diseases (EGIDs) Found on Eosinophils and Mast Cells in Human Tissue
Bradford A. Youngblood(Allakos (United States)), Kathryn Peterson(University of Utah), John Leung(Tufts University), Emily C. Brock(Allakos (United States)), Nenad Tomašević(Regenxbio (United States)), Henrik Rasmussen(University of Oslo), Christopher Bebbington(Curtin University)
Cited by 0
Related Papers
Chimeric Receptors Providing Both Primary and Costimulatory Signaling in T Cells from a Single Gene Product
|The Journal of Immunology|1998|546
Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis
|Gastroenterology|2015|328
Anti–Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis
|New England Journal of Medicine|2020|263
Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis
|Gastroenterology|2016|228
International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature
|Clinical Gastroenterology and Hepatology|2022|175